Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315417 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
A Phase 3 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT02315417 is a Phase 3 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 16 participants.
The verdict
NCT02315417, a Phase 3 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
Interventions
- DRUG Placebo
- DRUG gevokizumab
- DRUG gevokizumab open-label
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315417
The ClinicalTrials.gov registry entry for NCT02315417 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02315417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02315417 about?
NCT02315417 is a clinical study titled "An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum". The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
What is the current status of trial NCT02315417?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2014-11. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02315417?
The interventions under investigation include: Placebo (DRUG), gevokizumab (DRUG), gevokizumab open-label (DRUG).
Who is sponsoring clinical trial NCT02315417?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.